Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | VIRX |
---|---|---|
09:32 ET | 3563 | 0.7414 |
10:53 ET | 100 | 0.771 |
11:06 ET | 1100 | 0.77 |
11:09 ET | 1300 | 0.77 |
11:11 ET | 862 | 0.7701 |
11:13 ET | 1015 | 0.77 |
11:15 ET | 255 | 0.77 |
11:18 ET | 100 | 0.77005 |
11:24 ET | 647 | 0.770099 |
11:26 ET | 488 | 0.77 |
11:27 ET | 500 | 0.750051 |
12:21 ET | 9256 | 0.75 |
12:23 ET | 2230 | 0.7251 |
12:41 ET | 300 | 0.7251 |
01:01 ET | 2639 | 0.72 |
01:03 ET | 350 | 0.7404 |
01:15 ET | 224 | 0.7201 |
01:33 ET | 813 | 0.7202 |
01:42 ET | 2980 | 0.7404 |
01:44 ET | 1000 | 0.7202 |
01:57 ET | 200 | 0.759 |
02:02 ET | 100 | 0.7589 |
02:15 ET | 342 | 0.74 |
02:18 ET | 100 | 0.74005 |
02:40 ET | 300 | 0.74005 |
02:58 ET | 283 | 0.7404 |
03:02 ET | 100 | 0.7202 |
03:09 ET | 1900 | 0.76 |
03:18 ET | 150 | 0.758 |
03:48 ET | 1200 | 0.72 |
03:50 ET | 100 | 0.7288 |
03:52 ET | 1065 | 0.742 |
03:56 ET | 1500 | 0.7412 |
03:57 ET | 147 | 0.7412 |
03:59 ET | 100 | 0.7412 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Viracta Therapeutics Inc | 29.1M | -0.6x | --- |
Raphael Pharmaceutical Inc | 28.7M | -16.6x | --- |
ProMIS Neurosciences Inc | 30.1M | -1.9x | --- |
RenovoRx Inc | 30.4M | -1.8x | --- |
BioVie Inc | 27.5M | -0.5x | --- |
UNITY Biotechnology Inc | 27.4M | -0.7x | --- |
Viracta Therapeutics, Inc. is a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers, which impact patients worldwide. The Company’s lead product candidate is an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir (collectively, Nana-val). Nana-val is being evaluated in multiple ongoing clinical trials, including a pivotal, global, multicenter, open-label Phase II basket trial for the treatment of multiple subtypes of relapsed or refractory (R/R) Epstein-Barr virus-positive (EBV+) lymphoma (NAVAL-1), as well as a multinational, open-label Phase Ib/II clinical trial for the treatment of patients with recurrent or metastatic (R/M) EBV + nasopharyngeal carcinoma (NPC) and other advanced EBV + solid tumors. The Company is also pursuing the application of its Kick and Kill approach in other virus-related cancers.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $29.1M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 39.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.74 |
EPS | $-1.24 |
Book Value | $0.47 |
P/E Ratio | -0.6x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.